Brief: Xspray Says Dasynoc™ May Mitigate Increased Mortality In CML Treatment

Xspray Pharma publ AB

26/10/2023 14:39

Oct 26 (Reuters) - XSpray Pharma AB (publ)  XSPRAY.ST :
    * XSPRAY PUBLICATION DEMONSTRATES HIGH CONCOMITANT PPI AND
TKI USE
IN CML RESULTING IN RISK OF INCREASED MORTALITY WHICH MAY BE
MITIGATED BY DASYNOC™

Source text for Eikon:  ID:nMFN8ChzmT 
Further company coverage:  XSPRAY.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))